Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AAAP
CUSIPN/A
Phone33-04-50-99-30-70
Debt
Debt-to-Equity RatioN/A
Current Ratio5.49
Quick Ratio5.22
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$121.01 million
Price / Sales29.67
Cash FlowN/A
Price / CashN/A
Book Value$7.54 per share
Price / Book10.83
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-27,990,000.00
Net Margins-43.93%
Return on Equity-20.59%
Return on Assets-14.58%
Miscellaneous
Employees501
Outstanding Shares43,980,000
Advanced Accelerator Application (NASDAQ:AAAP) Frequently Asked Questions
What is Advanced Accelerator Application's stock symbol?
Advanced Accelerator Application trades on the NASDAQ under the ticker symbol "AAAP."
How were Advanced Accelerator Application's earnings last quarter?
Advanced Accelerator Application SA (NASDAQ:AAAP) issued its quarterly earnings results on Thursday, August, 31st. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The business had revenue of $40.14 million for the quarter, compared to analysts' expectations of $36.74 million. Advanced Accelerator Application had a negative return on equity of 20.59% and a negative net margin of 43.93%. View Advanced Accelerator Application's Earnings History.
When is Advanced Accelerator Application's next earnings date?
What price target have analysts set for AAAP?
4 Wall Street analysts have issued 12-month price targets for Advanced Accelerator Application's shares. Their forecasts range from $47.00 to $82.00. On average, they expect Advanced Accelerator Application's share price to reach $64.50 in the next twelve months. View Analyst Ratings for Advanced Accelerator Application.
Who are some of Advanced Accelerator Application's key competitors?
Some companies that are related to Advanced Accelerator Application include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Allergan (AGN) and Celgene (CELG).
Who are Advanced Accelerator Application's key executives?
Advanced Accelerator Application's management team includes the folowing people:
- Susanne Schaffert, Chairman of the Board
- Stefano Buono, Chief Executive Officer (Age 52)
- Heinz Mausli, Chief Financial Officer (Age 52)
- Gerard Ber, Chief Operating Officer (Age 57)
- Claude A. Hariton Ph.D., Head of Clinical Development (Age 59)
- Maurizio Franco Mariani, Global Head of Pre-Clinical Research (Age 55)
- Frederic Collet, Director
- Augusto Lima, Director
- Jessica Toepfer, Director
- Kapil Dhingra, Independent Director (Age 58)
When did Advanced Accelerator Application IPO?
(AAAP) raised $76 million in an initial public offering on Thursday, February 5th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.
Has Advanced Accelerator Application been receiving favorable news coverage?
Media headlines about AAAP stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Advanced Accelerator Application earned a coverage optimism score of 0.15 on Accern's scale. They also assigned media stories about the company an impact score of 46.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Advanced Accelerator Application?
Shares of AAAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Advanced Accelerator Application's stock price today?
One share of AAAP stock can currently be purchased for approximately $81.63.
How can I contact Advanced Accelerator Application?
Advanced Accelerator Application's mailing address is 20 Rue Diesel, Saint Genis Pouilly I0, 01630. The company can be reached via phone at 33-04-50-99-30-70 or via email at [email protected]
MarketBeat Community Rating for Advanced Accelerator Application (AAAP)
MarketBeat's community ratings are surveys of what our community members think about Advanced Accelerator Application and other stocks. Vote "Outperform" if you believe AAAP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AAAP will underperform the S&P 500 over the long term. You may vote once every thirty days.
